The plasma bradykinin-forming pathways and its interrelationships with complement

Molecular Immunology

Volumn 47, Issue 13, 2010, Pages 2161-2169

  Kaplan, Allen P ^a   Ghebrehiwet, Berhane ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Anaphylatoxin; Bradykinin; C1 Inhibitor; Complement; Factor XII; GC1qR; Kininogen; Prekallikrein

Indexed keywords

AMINOPEPTIDASE P; ANTIFIBRINOLYTIC AGENT; ARGININE CARBOXYPEPTIDASE; ARGIPRESSIN[DEGLYCINAMIDE]; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; BRADYKININ B2 RECEPTOR; CARBOXYPEPTIDASE TRANSPEPTIDASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT INHIBITOR; CYTOKERATIN 1; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; HEAT SHOCK PROTEIN 90; ICATIBANT; INTERLEUKIN 1; KALLIKREIN; KININOGEN; MEMBRANE METALLOENDOPEPTIDASE; OXYMETHOLONE; PROLINE CARBOXYPEPTIDASE; STANOZOLOL; UROKINASE RECEPTOR; ZINC;

ANGIONEUROTIC EDEMA; BINDING SITE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL REACTIVITY; CELL SURFACE; COMPLEMENT 1 INHIBITOR DEFICIENCY; COMPLEMENT 1 INHIBITORY DEFICIENCY; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DIABETIC NEUROPATHY; ENDOTHELIUM CELL; FEEDBACK SYSTEM; HUMAN; HYPERTENSION; IMMUNOELECTROPHORESIS; IMMUNOPATHOGENESIS; INFLAMMATION; INHERITANCE; INHIBITION KINETICS; KIDNEY DISEASE; MOLECULAR GENETICS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; BIOSYNTHETIC PATHWAYS; BRADYKININ; COMPLEMENT ACTIVATION; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT SYSTEM PROTEINS; FACTOR XII; HUMANS; KALLIKREINS; KININOGEN, HIGH-MOLECULAR-WEIGHT;

EID: 77954311687     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.05.010     Document Type: Review

References (105)

1. Alsenz J., Bork K., Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N. Engl. J. Med. 1987, 316:1360-1366.
2. Austen K.F., Sheffer A.L. Detection of hereditory angioneurotic edema by demonstration of a reduction in the second component of human complement. N. Engl. J. Med. 1965, 272:649-656.
3. Bas M., Bier H., Greve J., et al. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006, 61:1490-1492.
4. Binkley K., Davis Ar. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J. Allergy Clin. Immunol. 2000, 106:546-550.
5. Bock P., Shore J., Tans G., et al. Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J. Biol. Chem. 1985, 260:12434-12443.
6. Bokisch V., Muller-Eberhard H. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 1970, 49:2427-2436.
7. Bork K., Frank J., Grundt B., et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 2007, 119:1497-1503.
8. Bork K., Wulff K., Hardt J., et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J. Allergy Clin. Immunol. 2009, 124:129-134.
9. Byrd J., Shreevatsa A., Putlur P., et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J. Allergy Clin. Immunol. 2007, 120:403-408.
10. Caldwell J., Ruddy S., Schur P., et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1972, 1:39-52.
11. Cochrane C.G., Revak S.D. Dissemination of contact activation in plasma by plasma kallikrein. J. Exp. Med. 1980, 152:608-619.
12. Colman R.W., Pixley R.A., Najamunnisa S., et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 1997, 100:1481-1487.
13. Cugno M., Cicardi M., Coppola R., et al. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996, 33:361-364.
14. Curd J., Prograis L.J., Cochrane C. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. N. Engl. J. Med. 1980, 152:742-747.
15. Curd J., Yelvington M., Burridge N. Generation of bradykinin during incubation of hereditary angioedema plasma. Mol. Immunol. 1983, 19:1365.
16. Davis A., Perkins M. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br. J. Pharmacol. 1994, 113:63-68.
17. Dewald G., Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun. 2006, 343:1286-1289.
18. Donaldson V.H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J. Exp. Med. 1968, 127:411-429.
19. Donaldson V., Evans R. A biochemical abnormality in hereditary angioneurotic edema. Am. J. Med. 1963, 35:37-44.
20. Erdos E., Sloane G. An enzyme in human plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 1962, 11:585-592.
21. Fields T., Ghebrehiwet B., Kaplan A.P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J. Allergy Clin. Immunol. 1983, 72:54-60.
22. Ghebrehiwet B., Silverberg M., Kaplan A.P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 1981, 153:665-676.
23. Ghebrehiwet B., Randazzo B., Dunn J., et al. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 1983, 71:1450-1456.
24. Ghebrehiwet B., Lim B.L., Peerschke E.I., et al. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J. Exp. Med. 1994, 179:1809-1821.
25. Ghebrehiwet B., Lu P., Zhang W., et al. Evidence that the two C1q binding membrane proteins, gC1q-R and cC1q-R, associate to form a complex. J. Exp. Med. 1997, 179:1429-1436.
26. Griffin J.H. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc. Natl. Acad. Sci. U.S.A. 1978, 75:1998-2002.
27. Griffin J.H., Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:2554-2558.
28. Han E., MacFarlane R., Mulligan A., et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 2002, 8:1057-1063.
29. Harpel P., Lewin M., Kaplan A. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 1985, 260:4257-4263.
30. Hasan A.A., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3615-3620.
31. Hauptmann G., Lang J., North M., et al. Acquired C1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut 1976, 32:195-206.
32. He S., Sim R., Whaley K. Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes. Mol. Med. 1998, 4:119-128.
33. Herwald H., Dedio J., Kellner R., et al. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J. Biol. Chem. 1996, 271:13040-13047.
34. Jackson J., Sim R., Whaley K., et al. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J. Clin. Invest. 1989, 83:698-707.
35. Joseph, K., Kaplan, A. Unpublished observations.
36. Joseph K., Ghebrehiwet B., Peerschke E.I., et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8552-8557.
37. Joseph K., Ghebrehiwet B., Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin. Immunol. 1999, 92:246-255.
38. Joseph K., Ghebrehiwet B., Kaplan A.P. Activation of the kinin-forming cascade on the surface of endothelial cells. Biol. Chem. 2001, 382:71-75.
39. Joseph K., Tholanikunnel B., Kaplan A. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc. Natl. Acad. Sci. 2002, 99:896-900.
40. Joseph K., Tholanikunnel B.G., Ghebrehiwet B., et al. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb. Haemost. 2004, 91:61-70.
41. Joseph K., Tholanikunnel B., Kaplan A. Factor XII-independent cleavage of high molecular weight kininogen by prekallikrein and inhibition by C1 inhibitor. J. Allergy Clin. Immunol. 2009, 124:143-149.
42. Juhlin L., Michaelsson G. Vascular reactions in hereditary angioneurotic edema. Acta Derm. Venereol. 1969, 40:20-25.
43. Kaplan A.P., Austen K.F. A pre-albumin activator of prekallikrein. J. Immunol. 1970, 105:802-811.
44. Kaplan A.P., Austen K.F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. Exp. Med. 1971, 133:696-712.
45. Kaplan A., Silverberg M. Contact system and its disorders. Blood - Principles Practice of Hematology 1995, 1115-1131. Philadelphia Lippincott Williams and Wilkins. R. Handin, S. Lux, T. Stossel (Eds.).
46. Kaplan A., Greaves M., Angioedema J. Am. Acad. Dermatol. 2005, 53:373-388.
47. Kerbiriou D., Griffin J. Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J. Biol. Chem. 1979, 245:12020-12027.
48. Kew R., Fisher J., Webster R. Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J. Immunol. 1995, 155:5369-5374.
49. Kramer J., Katz Y., Rosen F., et al. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J. Clin. Invest. 1991, 87:1614-1620.
50. Kramer J., Rosen F., Colten H., et al. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J. Clin. Immunol. 1993, 91:1258-1262.
51. Mahdi F., Shariat-Madar Z., Todd R.F., et al. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001, 97:2342-2350.
52. Malbran A., Hammer C., Frank M., et al. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J. Allergy Clin. Immunol. 1988, 81:1199-1204.
53. Mandle R.J., Kaplan A. Hageman factor substrates: human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J. Biol. Chem. 1977, 252:6097-6104.
54. Mandle R., Colman R., Kaplan A. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human pl. Proc. Natl. Acad. Sci. 1976, 73:4179-4183.
55. Marceau F. Kinin B1 receptors: a review. Immunopharmacology 1995, 30:1-26.
56. Margolius H. Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin. Rev. Allergy Immunol. 1998, 16:337-349.
57. Martin L., Raison-Peyron N., Nothen M., et al. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J. Allergy Clin. Immunol. 2007, 120:975-977.
58. Mohanseenivasan, V., Dighe, S., Tholanikunnel, B., et al., Interaction of Factor XII with Vascular Endothelial Cells, submitted for publication.
59. Mori K., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J. Biochem. 1981, 89:1465-1473.
60. Motta G., Rojkjaer R., Hasan A.A., et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998, 91:516-528.
61. Nakayasu T., Nagasawa S. Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW)-kininogen. J. Biochem. 1979, 85:249-258.
62. Nishikawa K., Shibayama Y., Kuna P., et al. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood 1992, 80:1980-1988.
63. Nussberger J., Cugno M., Amstutz C., et al. Plasma bradykinin in angioedema. Lancet 1998, 351:1693-1697.
64. Nussberger J., Cugno M., Cicardi M., et al. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 1999, 104:1321-1322.
65. Pearson K., Buchignani J., Shimkin P., et al. Hereditary angioneurotic edema of the gastrointestinal tract. Am. J. Toetgenol. Radium Ther. Nucl. Med. 1972, 116:256-261.
66. Peerschke E.I, Smyth S.S., Teng E.I., et al. Human umbilical vein endothelial cells possess binding sites for the globular domain of C1Q. J. Immunol. 1996, 157:4154-4158.
67. Perez H., Kelly E., Chenoweth D., et al. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin). J. Clin. Invest. 1988, 82:360-363.
68. Pixley R., Schapira M., Colman R. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 1985, 260:1723-1729.
69. Quastel M., Harrison R., Cicardi M., et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 1983, 71:1041-1046.
70. Ratnoff O.D., Naff G.B. The conversion of C'IS to C'1 esterase by plasmin and trypsin. J. Exp. Med. 1967, 125:337-358.
71. Reddigari S., Kaplan A.P. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 1988, 71:1334-1340.
72. Reddigari S.R., Kuna P., Miragliotta G., et al. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 1993, 81:1306-1311.
73. Reddigari S.R., Shibayama Y., Brunnee T., et al. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J. Biol. Chem. 1993, 268:11982-11987.
74. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32:1-46.
75. Rojkjaer R., Hasan A.A., Motta G., et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb. Haemost. 1998, 80:74-81.
76. Ruddy S., Gigli I., Sheffer A., et al. The laboratory diagnosis of hereditary angioedema. Proceedings of the Sixth International Congress of Allergology 1968, 351-359. Excepta Medica, Amsterdam. N. Rose, M. Richter, A. Sehon (Eds.).
77. Schapira M., Silver L., Scott C., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 1983, 308:1050-1053.
78. Schmaier A.H. Contact activation: a revision. Thromb. Haemost. 1997, 78:101-107.
79. Schmaier A.H., Silver L., Adams A.L., et al. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb. Res. 1984, 33:51-67.
80. Schmaier A.H., Kuo A., Lundberg D., et al. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J. Biol. Chem. 1988, 263:16327-16333.
81. Schneider L., Lumry W., Vegh A., et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 2007, 120:416-422.
82. Schreiber A., Kaplan A., Austen K. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest. 1973, 52:1402-1409.
83. Schreiber A., Zweiman B., Atkins P., et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976, 48:567-580.
84. Shariat-Madar Z., Mahdi F., Schmaier A. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 2002, 277:17962-17969.
85. Sheikh I.A., Kaplan A.P. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem. Pharmacol. 1986, 35:1957-1963.
86. Sheikh I., Kaplan A. Studies of the digestion of bradykinin, Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochem. Pharmacol. 1986, 35:1951-1956.
87. Sheikh I.A., Kaplan A.P. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem. Pharmacol. 1989, 38:993-1000.
88. Shin H., Snyderman R., Friedman E., et al. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 1968, 162:361-363.
89. Silverberg M., Dunn J., Garen L., et al. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J. Biol. Chem. 1980, 255:7281-7286.
90. Silverberg M., Nicoll J., Kaplan A. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb. Res. 1980, 20:173-189.
91. Tait J.F., Fujikawa K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185-224 of the kininogen light chain retains full binding activity. J. Biol. Chem. 1986, 261:15396-15401.
92. Tait J.F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J. Biol. Chem. 1987, 262:11651-11656.
93. Tankersley D.L., Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984, 23:273-279.
94. Thompson R.E., Mandle R., Kaplan A.P. Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen. J. Exp. Med. 1978, 147:488-499.
95. Thompson R.E., Mandle R., Kaplan A.P. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:4862-4866.
96. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998, 119:358-365.
97. van Iwaarden F., de Groot P.G., Bouma B.N. The binding of high molecular weight kininogen to cultured human endothelial cells. J. Biol. Chem. 1988, 263:4698-4703.
98. Wallace E.M., Perkins S.J., Sim R.B., et al. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol. Med. 1997, 3:385-396.
99. Wiggins R.C., Bouma B.N., Cochrane C.G., et al. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:4636-4640.
100. Yang H., Erdos E. Second kininase in human blood plasma. Nature 1967, 215:1402-1403.
101. Zahedi R., Wisnieski J., Davis A.E. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J. Immunol. 1997, 159:983-988.
102. Zahedi R., Bissler J., Davis Ar, et al. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. J. Clin. Invest. 1995, 95:1299-1305.
103. Zhang X., Tan F., Zhang Y., et al. Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists. J. Biol. Chem. 2008, 283:7994-8004.
104. Zuraw B., Curd J. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J. Clin. Invest. 1986, 78:567-575.
105. Zuraw B., Sugimoto S., Curd J. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J. Allergy Clin. Immunol. 1986, 78:1115-1120.